Fixed Venetoclax Dosing May Not Be Feasible for All Patients With CLL

The retrospective cohort study evaluated data from 116 patients who received venetoclax as part of their first-line treatment and 145 patients in the relapsed/refractory setting..

Related Keywords

United States , ,Journal Of The National Comprehensive Cancer Network ,Astrazeneca Pharmaceuticals ,National Comprehensive Cancer ,Metrics Plus ,Southern United ,